Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ENDRA Life Sciences (NDRA) Enterprise Value (2017 - 2026)

ENDRA Life Sciences has reported Enterprise Value over the past 6 years, most recently at -$9.5 million for Q4 2021.

  • Quarterly Enterprise Value fell 30.91% to -$9.5 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$9.5 million through Dec 2021, down 30.91% year-over-year, with the annual reading at -$9.5 million for FY2021, 30.91% down from the prior year.
  • Enterprise Value was -$9.5 million for Q4 2021 at ENDRA Life Sciences, up from -$11.8 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$133679.0 in Q1 2017 and troughed at -$16.8 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$4.8 million (2017), against an average of -$5.7 million.
  • Year-over-year, Enterprise Value plummeted 9136.41% in 2017 and then skyrocketed 90.87% in 2018.
  • A 5-year view of Enterprise Value shows it stood at -$5.6 million in 2017, then decreased by 15.52% to -$6.5 million in 2018, then increased by 4.59% to -$6.2 million in 2019, then decreased by 17.06% to -$7.2 million in 2020, then plummeted by 30.91% to -$9.5 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Enterprise Value are -$9.5 million (Q4 2021), -$11.8 million (Q3 2021), and -$14.0 million (Q2 2021).